Zoetis (ZTS) Long-Term Debt Repayments (2016 - 2023)

Zoetis' (ZTS) quarterly Long-Term Debt Repayments came in at $1.4 billion in Q1 2023, up 170.0% on a QoQ basis from $500.0 million in Q4 2020.

Zoetis (ZTS) Long-Term Debt Repayments (2016 - 2023) Analysis & Trends

Zoetis (ZTS) has 4 years of Long-Term Debt Repayments data on file, last reported at $1.4 billion in Q1 2023.

On a quarterly basis, Long-Term Debt Repayments changed N/A year-over-year to $1.4 billion in Q1 2023; TTM through Dec 2023 was $1.4 billion, a N/A change from a year earlier, with the FY2025 full-year figure at $1.4 billion, changed N/A from the prior year.
Long-Term Debt Repayments for Q1 2023 stood at $1.4 billion, up from $500.0 million in the prior quarter.
Over the last five years, Long-Term Debt Repayments for ZTS reached as high as $1.4 billion in Q1 2023 and fell as low as $500.0 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	23.00 Mn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	-
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	-478.39 Mn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	-
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	-
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	-
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	-
10	Vireo Growth	10.57 Bn	10.41 Bn	59.30 Mn	-

Download Data